HB 1425
In CommitteeHouse
Pharmacogenomic testing
Requiring coverage of pharmacogenomic testing for psychotropic medications.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill requires both private health insurers and Washington’s Medicaid program to cover genetic testing that helps doctors choose the best psychotropic medications for patients—without requiring prior approval or trying other medications first. The goal is to improve mental health treatment outcomes by using science to guide prescribing decisions.
- Requires private health insurers to cover pharmacogenetic testing for psychotropic medications (e.g., antidepressants, antipsychotics) without prior authorization or step therapy (i.e., patients don’t have to try and fail other meds first).
- Requires Washington’s Medicaid program (including managed care organizations) to cover the same testing by January 1, 2026, with the same no-barrier rules.
- Defines coverage as required only when testing is supported by scientific evidence—including FDA approval, CMS guidelines, or nationally recognized clinical practice guidelines.
- Expands the list of laws that apply to state employee health plans to include the new pharmacogenetic coverage rules.
- Includes definitions for key terms like *pharmacogenetic testing* (analysis of genes affecting how the body processes medications) and *consensus statements* (expert-developed clinical guidance).
Who is affected
- Private health plan members — Members of private health insurance plans who receive psychotropic medications (e.g., for depression, anxiety, bipolar disorder) will have access to pharmacogenetic testing without needing prior approval or trying and failing on other medications first.
- Medicaid (Apple Health) enrollees — People enrolled in Washington’s Medicaid program (Apple Health) and those in Medicaid-managed care plans will gain access to the same testing under the same rules as private plans.
- Health care providers — Primary care providers and psychiatrists who prescribe psychotropic medications will be able to use genetic testing to guide more personalized and effective treatment decisions.
- People with mental health conditions — Individuals with mental health conditions—especially those who have not responded to previous medications—may experience faster symptom relief and reduced risk of hospitalization.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
Eliminating prior authorization and step therapy for pharmacogenetic testing removes a major barrier to timely, evidence-based mental health care—especially for patients who have failed multiple medications and are at high risk of deterioration, hospitalization, or suicide.
HealthcarePeopleRef: Sec. 2(2); Sec. 4(2)By requiring coverage for pharmacogenetic testing in both private plans and Medicaid (Apple Health), the bill extends equitable access to precision mental health care across income and insurance status—potentially reducing disparities in treatment response and outcomes for low-income and historically underserved populations.
HealthcarePeopleRef: Sec. 2(1); Sec. 4(1)The bill’s evidence-based coverage standard (FDA approval, CMS guidelines, consensus statements) ensures that only clinically validated tests are covered—protecting patients from costly, unproven, or misleading direct-to-consumer genetic tests while promoting scientifically sound care.
HealthcarePeopleRef: Sec. 2(3); Sec. 4(3)The definition of pharmacogenetic testing includes both single-gene and multigene panels, enabling broader clinical utility—allowing providers to use comprehensive tests (e.g., CYP2D6/CYP2C19 panels) rather than being limited to fragmented, less informative single-gene assays.
HealthcarePeopleRef: Sec. 2(4)(a); Sec. 4(4)By reducing psychiatric hospitalizations (studies cited in bill show ~40% reduction), the bill may decrease emergency response and law enforcement involvement in mental health crises—freeing resources for community-based care and reducing incarceration of people in crisis.
Public SafetyPeopleRef: Sec. 2(1); Sec. 4(1)
Potential Concerns (4)
The bill mandates coverage of pharmacogenetic testing without prior authorization or step therapy, which may increase short-term insurer and state Medicaid program costs. While the legislature projects long-term savings through reduced hospitalizations, the immediate fiscal burden falls on insurers and the state—potentially leading to higher premiums or taxes if cost projections prove optimistic.
FinancialPeopleRef: Sec. 2(3); Sec. 4(3)Private health insurers and Medicaid managed care organizations must absorb new administrative and clinical integration costs (e.g., lab coordination, EHR updates, staff training), which may strain smaller insurers or lead to reduced provider network flexibility or plan changes—potentially limiting consumer choice in competitive markets.
Business & EmploymentPeopleRef: Sec. 2(1); Sec. 4(1)The requirement that testing be supported by “scientific evidence” (including FDA approval, CMS guidelines, or consensus statements) may delay or limit access to emerging or niche tests that lack broad consensus but show clinical promise—potentially excluding innovative but less-established assays from coverage.
HealthcareLean peopleRef: Sec. 2(3); Sec. 4(3)Without specifying payment rates or reimbursement standards, the bill may lead to inconsistent or delayed access to testing depending on insurer or MCO contracting with labs—especially in rural or underserved areas where lab networks are limited.
HealthcareLean peopleRef: Sec. 2(1); Sec. 4(1)
Who Is Most Affected
Patients with depression, anxiety, bipolar disorder, or other conditions treated with psychotropic medications—especially those who have failed multiple prior treatments—stand to gain faster, more effective care and reduced risk of hospitalization or suicide. This is especially impactful for Medicaid enrollees and underinsured individuals who previously faced financial and administrative barriers to advanced testing.
Primary care providers and psychiatrists gain a powerful clinical tool to personalize treatment, reducing trial-and-error prescribing and improving outcomes. However, they must also absorb new responsibilities (e.g., ordering tests, interpreting results, counseling patients) without additional reimbursement specified in the bill.
Large commercial insurers and Medicaid MCOs face new administrative and clinical integration costs. While long-term savings from reduced hospitalizations are projected, short-term budget pressures may lead to cost-shifting (e.g., narrower lab networks, slower adoption). Smaller insurers may struggle more with implementation.
Genetic testing labs and molecular diagnostics companies stand to gain significant new revenue from mandated coverage, especially those whose tests meet the bill’s evidence standards (e.g., FDA-cleared or guideline-endorsed panels). Smaller or emerging labs may be excluded if they lack validation or consensus support.
State government (including DHSS and Medicaid agency) faces upfront implementation and administrative costs but may realize net savings from reduced psychiatric hospitalizations and emergency services. The bill’s federal funding clause (Sec. 4(5)) helps offset this, but success depends on federal matching rates and administrative capacity.